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ABSTRACT 51 
 52 
Background: Oral bacteria are the main trigger for the development of periodontitis 53 
and some species are known to modulate neutrophil function. This study aimed to 54 
explore the release of neutrophil extracellular traps (NETs), associated antimicrobial 55 
proteins and reactive oxygen species (ROS) in response to periodontal bacteria, as 56 
well as the underlying pathways.  57 
Methods: Isolated peripheral blood neutrophils were stimulated with 19 periodontal 58 
bacteria. NET and ROS release as well as the expression of NET-bound 59 
antimicrobial proteins, elastase, myeloperoxidase and cathepsin G, in response to 60 
these species were measured using fluorescence-based assays. NET and ROS 61 
release were monitored after the addition of nicotinamide adenine dinucleotide 62 
phosphate (NADPH)-oxidase pathway modulators and inhibitors of Toll-like 63 
receptors (TLRs). Moreover, bacterial entrapment by NETs was visualised 64 
microscopically and bacterial killing was assessed by bacterial culture. 65 
Results: Certain microorganisms, e.g. Veillonella parvula and Streptococcus 66 
gordonii, stimulated higher ROS and NET release than others. NETs were found to 67 
entrap, but not kill, all periodontal bacteria tested. NADPH-oxidase pathway 68 
modulators decreased ROS but not NET production in response to the bacteria. 69 
Interestingly, TLR inhibitors did not impact on ROS and NET release.    70 
Conclusions: These data suggest that the variability in neutrophil response towards 71 
different bacteria may contribute to the pathogenesis of periodontal diseases by 72 
mechanisms such as bacterial avoidance of host responses and activation of 73 
neutrophils. Moreover, our results indicate that bacteria-stimulated NET release may 74 
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in part arise via NADPH oxidase-independent mechanisms. The role of TLR 75 
signalling in bacteria-induced ROS and NET release needs to be further elucidated.  76 
 77 
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INTRODUCTION 100 
 101 
Periodontitis is initiated by the accumulation of microbial biofilms at and below the 102 
gingival margin. Indeed it has been estimated that ~700 oral bacterial species and 103 
~1,200 predominant phylotypes exist (1-3). Of these bacterial species, 5 major 104 
bacterial complexes (red, orange, yellow, green and purple) have been identified by 105 
Socransky et al. using DNA probes (4). The clustering and ordination analysis 106 
allowed them to assign microbial species to a colour complex dependent upon the 107 
strength of association with each other and the clinical staging of periodontitis. The 108 
biofilms, which develop during disease, are orchestrated to maximise their 109 
adherence, communication and survival. The accumulation of bacterial species 110 
within the biofilm enables its development and perseverance, and certain bacteria, 111 
such as Fusobacterium nucleatum (F. nucleatum), are key orchestrators of biofilm 112 
formation and maturation (5). 113 
  114 
In susceptible individuals, dysbiosis and an aberrant host-microbial equilibrium can 115 
result in the onset of disease (6), where the microbial biofilm thrives by exploiting the 116 
host inflammatory response. This process fuels a vicious cycle of bacterial 117 
accumulation, inflammation and subsequent tissue destruction. The acute 118 
inflammatory reaction is predominantly mediated by neutrophils and is initially 119 
protective, via activation of innate neutrophil-derived defence mechanisms and also 120 
the activation of the acquired cellular and humoral immune system. In periodontitis, 121 
however, the aberrant neutrophil response is reputed to contribute to collateral tissue 122 
damage and formation of disease-associated molecular patterns, which perpetuate 123 
the inflammation leading to chronicity (7). Furthermore, the inflammatory state itself 124 
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supplies nutrients to pathogenic bacteria such as Porphyromonas gingivalis (P. 125 
gingivalis), e.g. iron from heme, supporting its survival and proliferation (8). 126 
  127 
An exaggerated immune activity is also observed in peripheral blood neutrophils 128 
from both chronic and aggressive periodontitis patients. These neutrophils are 129 
reportedly hyper-reactive in response to a microbial challenge in terms of their 130 
release of reactive oxygen species (ROS), but also hyperactive in the absence of an 131 
exogenous stimulus (9-11). In addition, excessive neutrophil-driven proteolytic 132 
activity and pro-inflammatory cytokine production have been observed in 133 
periodontitis and associate with pathogenicity (7). One of the mechanisms by which 134 
neutrophils combat microorganisms through the production of neutrophil extracellular 135 
traps (NETs), whereby decondensed DNA is released into the extracellular 136 
environment to immobilise and potentially kill invading bacteria. NET release is 137 
reported to be dependent on the production of ROS, such as hydrogen peroxide 138 
(H2O2), via superoxide generation by the enzyme NADPH oxidase (12). 139 
   140 
Little is known about the differential interactions between oral bacteria and 141 
neutrophils, however there is evidence that certain species and strains can evoke 142 
different neutrophil responses (13-16). This study aimed to elucidate the ability of 143 
bacterial species and strains frequently isolated from the oral cavity of healthy and 144 
diseased individuals to activate ROS and NET responses in neutrophils. The ability 145 
of NETs to entrap and kill bacteria, along with the expression of the antimicrobial and 146 
NET-associated proteins neutrophil elastase (NE), myeloperoxidase (MPO) and 147 
cathepsin G (CG) were also analysed. 148 
 149 
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 150 
RESULTS 151 
 152 
Neutrophil ROS release in response to periodontal bacteria  153 
The production of total ROS, extracellular ROS and superoxide in response to 19 154 
periodontal bacteria and S. aureus (Table 1) were determined. Certain bacteria 155 
elicited higher total ROS production in neutrophils, which was measured by luminol 156 
chemiluminescence. This was statistically significant for P. acnes, S. anginosus and 157 
C. rectus as well as the positive control opsonised S. aureus (Figure 1A). Consistent 158 
with the data expressed as total peak ROS production, time-course ROS production 159 
expressed as “area under the curve” demonstrated that ROS production was highest 160 
in response to opsonised S. aureus followed by S. anginosus. Notably, the increase 161 
in total ROS in response to opsonised S. aureus was more rapid than following direct 162 
stimulation with periodontal bacteria, as illustrated by the sharp elevation of the 163 
curve immediately following stimulation. Neutrophil extracellular ROS production was 164 
subsequently analysed by isoluminol chemiluminescence. Phorbol 12-myristate 13-165 
acetate (PMA; positive control) and S. gordonii induced significantly higher 166 
extracellular ROS than PBS treatment (negative control) (Figure 1B). The steep 167 
time-course curve in response to PMA indicates a rapid neutrophil response. 168 
Neutrophil extracellular superoxide production was measured using lucigenin. PMA 169 
and opsonised S. aureus did not induce significantly higher superoxide production 170 
relative to the PBS control. However, some periodontal bacteria increased 171 
extracellular superoxide production in neutrophils, which was statistically significant 172 
for S. anginosus, C. suptigena, and F. nucleatum subsp. nucleatum (Figure 1C).  173 
 174 
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Quantification of NET production in response to periodontal bacteria 175 
NET release in response to the bacterial challenge was quantified. Some bacteria 176 
led to an enhanced NET-DNA production, which was statistically significant for P. 177 
acnes, V. parvula, and S. gordonii compared with the PBS control (Figure 2A). NET-178 
bound NE, MPO and CG were quantified colorimetrically and data demonstrated that 179 
certain periodontal bacteria elicited an increased production of NET-bound proteins 180 
relative to PBS (Figure 2B-D). Similarly, stimulation with PMA and opsonised 181 
S. aureus (positive controls) induced statistically significant elevations in MPO and 182 
CG expression (Figures 2C and D).  183 
 184 
NET entrapment of bacteria does not associate with Socransky complexes or 185 
with bacterial cell death 186 
For clinical relevance, data are presented by grouping periodontal bacteria according 187 
to the Socransky complexes (4) (Figure 3A). Non-Socransky complex: l. noxia and 188 
V. parvula were found to be entrapped within NET structures in higher numbers 189 
compared to the negative controls (unstimulated neutrophils or degraded NETs) 190 
However, neither A. actinomycetemcomitans (serotype b) nor P. acnes or A. 191 
viscosus were significantly associated with NET entrapment. Yellow complex: S. 192 
anginosus and S. gordonii were significantly entrapped within NETs. However, the 193 
other yellow complex bacteria assayed, S. sanguinis, S. oralis and S. intermedius, 194 
were not found within NET structures. Green complex: none of the green complex 195 
bacteria assayed appeared within NETs at a significant level. Orange complex: C. 196 
rectus, C. showae and F. nucleatum subsp. polymorphum were significantly 197 
entrapped within NETs relative to the negative controls, whereas S. constellatus and 198 
F. nucleatum subsp. nucleatum were not. Red complex: P. gingivalis was 199 
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significantly associated with NET structures compared with bacteria incubated with 200 
unstimulated neutrophils or degraded NET structures. SEM images of unstimulated 201 
neutrophils demonstrated spherical cells with no NET structures evident, whereas 202 
neutrophils incubated with A. actinomycetemcomitans serotype a, V. parvula and A. 203 
viscosus revealed the release of NET structures (Figure 3B). The strand-like 204 
filaments between the neutrophils appeared to associate with bacteria, for example, 205 
A. actinomycetemcomitans (serotype a) clustered along NET structures. The 206 
bacterial killing assays employed to detect the microbicidal properties of NETs 207 
revealed that the viablitiy of the 6 periodontal bacteria tested was unaffected by NET 208 
trapping (Figure 3C). 209 
 210 
Effect of NADPH-oxidase pathway modulating agents on ROS and NET 211 
production  212 
Components of the NADPH-oxidase signalling pathway were targeted in order to 213 
assess whether NADPH-oxidase is essential for neutrophil ROS and NET production 214 
in response to periodontal bacteria. The data show that diphenyleneiodonium (DPI; 215 
NADPH-oxidase inhibitor), N-acetyl-cysteine (NAC; H2O2 scavenger) and taurine 216 
(HOCl scavenger) treatment resulted in a reduction in total ROS release in response 217 
to all stimuli. This was statistically significant for PMA, opsonised S. aureus, S. 218 
gordonii, C. rectus, F. nucleatum subsp. polymorphum and S. noxia (Figure 4A). 219 
NET production was, with the exception of PMA, not significantly affected by these 220 
inhibitors, however, a moderate reduction of NET release was visible in all samples 221 
(Figure 4B). 222 
 223 
Effect of Toll-like receptor (TLR) inhibition on ROS and NET production  224 
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The role of TLR signalling in neutrophil ROS and NET responses to periodontal 225 
bacteria was investigated by using specific inhibitors. Chloroquine (TLR3, 7 and 9 226 
inhibitor) and oxidised 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine 227 
(OxPAPC; (TLR2 and 4 inhibitor) treatment as well as treatment with both 228 
components did not reduce ROS production by neutrophils. However, a significant 229 
increase in ROS release from neutrophils treated with OxPAPC and opsonised S. 230 
aureus was seen (Figure 5A). Similarly, NET release in response to bacterial 231 
stimulation was not affected by the TLR inhibitors (Figure 5B). 232 
 233 
 234 
DISCUSSION 235 
 236 
Neutrophil ROS production is a vital component of the innate immune response, 237 
which enables killing and clearance of pathogens. Neutrophils are the predominant 238 
immune cell in periodontitis (17), and the results presented here support that their 239 
stimulation with periodontal bacteria promotes extracellular, intracellular and 240 
superoxide ROS release; however data indicate that this may be species specific. 241 
Indeed, some species consistently elicited higher neutrophil ROS production while 242 
other bacteria, such as P. gingivalis or S. sanguinis, were not found to significantly 243 
promote ROS release. Bacteria like P. gingivalis, F. nucleatum and oral streptococci 244 
can scavenge neutrophil-derived ROS production, which is attributed to a range of 245 
oxidative stress response genes encoding proteins like rubrerythrin, glutathione 246 
peroxidase, glutaredoxin, NADH oxidase and superoxide dismutase (18-22). It is 247 
possible that these bacterial defence mechanisms may function to afford protection 248 
to other biofilm organisms that are less resistant to ROS.  249 
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 250 
Periodontitis is known to arise from an exaggerated inflammatory response to 251 
microbial plaque (6). Whilst it is recognised that ROS facilitate microbial killing, ROS 252 
do not discriminate between pathogens and host tissues, and therefore tissue injury 253 
can arise from excess plaque-induced extracellular ROS release. ROS are reported 254 
to contribute to periodontitis progression by direct and indirect mechanisms, 255 
including tissue damage (23, 24), lipid peroxidation (25), DNA strand breakage (26), 256 
increased osteoclast differentiation (27) and initiation of a self-perpetuating cycle that 257 
activates chronic immune cell-derived ROS production (28). Notably, Matthews et al. 258 
showed an increased ROS production by peripheral blood neutrophils in chronic 259 
periodontitis (9, 10). In patients susceptible to the deleterious effects of ROS, a 260 
discordance between oxidant and antioxidant levels may also play a role. This is 261 
supported by Chapple et al., who demonstrated that total antioxidant activity is lower 262 
in the saliva of periodontitis patients (29). It has also been reported that neutrophil 263 
chemotaxis is compromised in chronic periodontitis, and that these patients’ 264 
neutrophils produce the chemoattractant interleukin-8 in excess when stimulated, 265 
potentially creating distracted chemotaxis (30). Such processes may increase 266 
neutrophil tissue transit times and thereby potentially exacerbating ROS-mediated 267 
collateral tissue damage (17). 268 
 269 
Quantification of NET-DNA and NET-bound antimicrobial proteins demonstrated 270 
differential NET production in response to the periodontal bacteria tested. DNA is 271 
released during other forms of neutrophil cell death, such as necrosis, and the 272 
quantification of NET-bound components (NE, MPO and CG) therefore provides a 273 
DNA-independent measure of NETs. It is noteworthy that differences between 274 
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individuals have been reported, such as neutrophil responsiveness to stimuli, which 275 
can also affect NET quantification results regardless of the analytical method 276 
employed (31, 32). Significant NET production in response to individual periodontal 277 
bacteria, however, indicates these events likely occur in vivo. Notably, NETs have 278 
previously been shown to exist in purulent exudate from periodontal pockets, where 279 
they are postulated to entrap invading microbes and prevent their dissemination (33, 280 
34). Recently, many periodontal bacterial species have been shown to release 281 
DNAses, which in addition to regulating biofilm formation (35), can potentially 282 
disassemble NET structures to enable NET evasion (36). Thus, bacterial DNAse 283 
expression may explain why some periodontal species showed less entrapment, 284 
such as S. constellatus, which reportedly releases large quantities of DNAse (36).  285 
 286 
Following bacterial entrapment, the high local concentration of antimicrobial proteins 287 
associated with NETs is thought to disable and kill pathogens (37). In the present 288 
study, the incubation of NETs with periodontal bacteria did not impede bacterial 289 
growth or survival, being in accordance with data reported by Menegazzi et al. (38). 290 
Cytochalasin B was applied in our study to exclude the possibility of bacterial killing 291 
through phagocytosis and this inhibition occurs via blocking of actin polymerization 292 
(39). As functional actin filaments may play a role in NET formation (40), it is 293 
possible that cytochalasin B interfered with NET and antimicrobial protein release in 294 
our study and thus prevented bacterial killing. However, other known inhibitors of 295 
phagocytosis and endocytosis such as Latrunculin A or CK666 also exert their 296 
effects by disturbing actin polymerisation (41, 42). Future experiments may be 297 
directed at investigating differences among such inhibitors regarding their 298 
interference with NET release. 299 
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 300 
Treatment of neutrophils with the NADPH-oxidase inhibitor DPI, glutathione 301 
peroxidase precursor substrate NAC and the HOCl scavenger taurine abrogated 302 
total ROS release, being in accordance with data previously reported (43-45). NET 303 
release was only inhibited marginally in response to the bacterial challenge. At the 304 
same time, NET production was significantly affected by the inhibitors in neutrophils 305 
stimulated with PMA. This may be explained by the fact that PMA induces NETs via 306 
protein kinase C, which then activates the NADPH oxidase, and thus can elicit NETs 307 
only via the generation of ROS (43). These findings indicate that NADPH-oxidase-308 
independent NET formation may play a role in host defence against periodontal 309 
bacteria (46, 47).  310 
 311 
Further experiments aimed to establish the role of TLR activation in NET production. 312 
Pre-treatment of neutrophils with the intracellular TLR3, 7, 8 and 9 inhibitor 313 
chloroquine and with the TLR2 and 4 inhibitor OxPAPC separately or combined, did 314 
not lead to significant reductions in ROS or NET release. Previous findings have 315 
suggested that ROS release is both TLR2 and 4 dependent (48), however, Gould et 316 
al. recently demonstrated that blocking TLR2 and 4 did not abolish NET release (49), 317 
being in line with the findings of this study. Notably, neutrophils are not responsive to 318 
TLR3 ligands (50), therefore, the involvement of TLR7, 8 and 9 was investigated by 319 
using chloroquine. Similarly, to our results, Salmon et al. found that chloroquine had 320 
no effect on the oxidative metaboslism in neutrophils (51). Thus, a lack of inhibition 321 
of ROS and NET generation by chloroquine and OxPAPC indicates that other 322 
signalling pathways may have played a role in this study. For example, C-type lectin 323 
receptors and NOD-like receptors can be activated by bacterial triggers, and both 324 
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have been reported to induce immune activation in neutrophils, including the release 325 
of ROS (52, 53). Moreover, signalling via TLR co-receptors may have bypassed the 326 
inhibited pathways (54). Importantly, although widely used as a TLR inhibitor, 327 
chloroquine is thought to directly interfere with multiple physiological cell functions 328 
 including chemotaxis, phagocytosis and ROS release, by alkalising lysosomes and 329 
phagolysosomes (55, 56). Our results do not support an inhibitory effect of 330 
chloroquine on these functions in the concentrations applied in the present study, as 331 
no significant differences were seen between neutrophils treated with chloroquine 332 
and negative controls. However, results from functional cell assays using 333 
chloroquine as an inhibitor should be interpreted with care.  334 
 335 
Future experiments should target these receptors to further elucidate their specific 336 
role in ROS and NET release. Interestingly, in OxPAPC-treated neutrophils 337 
stimulated with opsonised S. aureus, a significant increase in ROS was seen. 338 
Previous studies reported that OxPAPC has the potential to increase ROS release in 339 
endothelial cells via activating the NADPH oxidase (57, 58). Moreover, Fc gamma 340 
receptor (FcγR) signalling is known to trigger ROS release (59). It is therefore 341 
possible that OxPAPC may act as a co-trigger of FcγR-mediated ROS release in 342 
neutrophils challenged with opsonised bacteria, however, further experiments are 343 
required to confirm this hypothesis. 344 
 345 
As a limitation of this study, planktonic single-species preparations were used to 346 
stimulate neutrophils. In vivo, however, neutrophils are challenged by multi-species 347 
biofilms. These biofilms produce metabolites and extracellular matrix components 348 
that may lead to a different response pattern compared to that observed under our 349 
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experimental conditions. Variability in these extracellular products generated by 350 
naturally or artificially grown biofilms is high and reproducibility of experiments 351 
involving such biofilms is difficult (13, 60). Moreover, natural dental biofilms are 352 
highly variable in their composition, and it is difficult to attribute their activation of 353 
neutrophils to certain species or biofilm components. Therefore, little is know about 354 
the interactions between host cells and mixed species biofilms. Further efforts aimed 355 
at creating a reproducible neutrophil-biofilm interaction model in vitro are currently 356 
being carried out by our group. Nevertheless, in order to understand the interaction 357 
of neutrophils with oral bacterial species, such microorganisms playing key roles in 358 
neutrophil activation need to be identified and investigated separately. Insights from 359 
these experiments may subsequently allow for better understanding of neutrophil 360 
responses to oral biofilms.  361 
 362 
As a further limitation, heat-killed microorganisms were employed in our study. 363 
Although heat-killing may lead to the denaturation of surface antigens and pathogen-364 
associated molecular patterns (PAMPs), this is thought to be reversible at 365 
temperatures below 80°C (61). Moreover, previous studies using live bacteria (A. 366 
actinomycetemcomitans serotype b or S. gordonii, F. nucleatum subsp. 367 
polymorphum and V. parvula) showed similar NET formation outcomes regarding 368 
AFU measurements or relative differences in NET production, respectively (14, 62). 369 
Another restriction in our study is the limited number of different bacterial species 370 
used to investigate neutrophil activation. Future studies may need to include further 371 
species, particularly of the red complex, such as Treponema denticola and 372 
Tannerella forsythia.  373 
 374 
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In the present study, neutrophils from periodontally and systemically healthy donors 375 
were used. Overall, these neutrophils were responsive to some health-associated 376 
species and opportunistic pathogens rather than disease-associated species. By 377 
contrast, our previous investigations of periodontally diseased patients have shown 378 
that their neutrophils are hyperactive and hyper-reactive towards F. nucleatum and 379 
P. gingivalis in terms of ROS and cytokine release. On the other hand, NET 380 
production in response to various stimuli was not altered and was similar in 381 
periodontitis patients and non-periodontitis controls. However, these studies did not 382 
compare the effect of health- and disease-associated bacteria on neutrophils (9, 30, 383 
63, 64). It is possible that neutrophils from periodontitis patients may show a higher 384 
reactivity towards periodontal bacteria than those from healthy subjects, as these 385 
neutrophils may be primed in the circulation by bacterial components, such as LPS, 386 
accessing the blood stream through periodontal microlesions (65, 66). Further 387 
studies examining responses of neutrophils from healthy and periodontally diseased 388 
individuals to different oral bacteria may shed light on possible mechanisms of 389 
immune tolerance in health and disease.     390 
 391 
In summary, the data presented here demonstrate variability between periodontal 392 
bacteria in their ability to stimulate neutrophil ROS production and NET responses. 393 
This may contribute to the pathogenesis of periodontitis by mechanisms such as 394 
bacterial avoidance of host defence mechanisms and thus persistence of infection, 395 
or excess ROS release with associated tissue damage. Moreover, our results 396 
indicate that innate immune receptors other than the TLRs investigated here may be 397 
involved in bacteria-triggered ROS and NET release, and that NADPH oxidase-398 
independent NET formation may occur in response to periodontal pathogens. 399 
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Comprehensive studies are required to fully elucidate the role of NETs and ROS in 400 
periodontitis, in particular with regard to the receptors, activation pathways and 401 
intracellular responses triggered by different bacteria. Also, investigating the possible 402 
activation of protective mechanisms, such as glutathione up-regulation, or of anti-403 
inflammatory signalling routes by these bacteria may improve our understanding of 404 
their differential effects seen in this study. 405 
 406 
 407 
MATERIALS AND METHODS 408 
 409 
Neutrophil isolation 410 
Neutrophils were isolated from the peripheral venous blood of periodontally and 411 
systemically healthy volunteers (University of Birmingham Ethics Reference: 412 
ERN_13-0325) using discontinuous Percoll gradients (GE Healthcare, Amersham, 413 
UK) as previously described (67). The medical history was taken from each donor 414 
and periodontal examinations were conducted to ensure periodontal and systemic 415 
health. Cell viability and purity were confirmed by trypan blue exclusion and flow 416 
cytometry, respectively, and this was typically >98%. 417 
 418 
Bacterial culture  419 
A panel of 19 periodontal bacteria and opsonised S. aureus were employed to 420 
stimulate neutrophils. Bacterial stocks were originally obtained from the Forsyth 421 
Institute (Boston, MA, USA) or purchased from the American Type Culture Collection 422 
(ATCC). Blood agar plates (Base no. 2 with 7% horse blood) were purchased from 423 
Oxoid (Basingstoke, UK) and used for growing most bacterial strains. P. gingivalis 424 
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(strain W83) was cultured on anaerobic 20% blood agar plates (Wilkins Chalgren, 425 
Oxoid) and S. aureus was cultured on tryptone soya agar (TSA) plates. Trypticase 426 
soy broth (TSB), brain heart infusion broth (BHI) (both from Oxoid) or fastidious 427 
anaerobe broth (Lab M, Heywood, UK) were used for planktonic growth of the 428 
microorganisms. Bacterial cell suspensions were measured spectrophotometrically 429 
at an optical density of 600 nm to estimate bacterial numbers and bacteria were 430 
heat-killed at 80°C for 30 min. Bacterial cells were washed with PBS, centrifuged and 431 
the pellet resuspended to produce a stock solution, which was stored at -20°C prior 432 
to use. The bacteria used, their growth conditions and assignment to Socransky 433 
complexes are listed in Table 1. 434 
 435 
Opsonisation of S. aureus 436 
S. aureus was grown planktonically in TSB. Following 48h of aerobic growth, 437 
bacteria were washed and pelleted by centrifugation for 15 min at 1800 rcf and 4°C. 438 
Bacteria were opsonised with Vigam liquid (5 mg/mL IgG, Bio Products Laboratory, 439 
Borehamwood, UK). This mixture was agitated overnight at room temperature and, 440 
after washing, stored at -20°C until needed. 441 
 442 
Stimuli employed to activate neutrophils  443 
Neutrophils were stimulated using a range of stimuli. PMA targets NET production 444 
via the activation of protein kinase C (PKC). Our previous findings demonstrated that 445 
the concentration of PMA required for NET release is at 50 nM, whereas 25 nM are 446 
sufficient to stimulate ROS production (43). Both Gram-positive and -negative 447 
bacteria were used to activate neutrophils via TLR2 and 4 in ROS and NET assays. 448 
In addition, ROS and NETs were produced in response to stimulation with opsonised 449 
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S. aureus, which activates neutrophils via the FcγR. For some supplementary 450 
assays, a smaller panel of bacteria was employed, where the selection was made 451 
based on variable characteristics of the microorganisms: Gram-positive and Gram-452 
negative, aerobic, anaerobic and microaerophilic bacteria from different complexes 453 
with FcγR and TLR activation properties were chosen, and both health and disease-454 
associated bacteria were represented. Moreover, variable DNase production was a 455 
selection criterion, as DNAses have the ability to disassemble NETs (e.g., F. 456 
nucleatum and S. aureus are known to produce DNase, whereas A. viscosus and V. 457 
parvula produce little or no DNase, respectively) (36). In addition, bacteria reported 458 
to interfere with ROS scavenging were included: F. nucleatum and S. noxia, which 459 
can metabolise the antioxidants glutathione and L-cysteine (68), as well as A. 460 
viscosus, which produces the ROS scavenger catalase (69). 461 
 462 
Quantification of NET production in response to periodontal bacteria 463 
NET release was determined using a NET quantification assay previously described 464 
(70). Neutrophils were stimulated with the positive controls PMA (50 nM) and 465 
opsonised S. aureus as well as with 19 heat-killed periodontal bacteria (multiplicity of 466 
infection [MOI] of 1,000 (71)) after being equilibrated for a 30 min baseline period. 467 
Unstimulated neutrophils (PBS) were employed as negative controls. Neutrophils 468 
from 10 periodontally and systemically healthy donors were used to perform NET 469 
quantification in triplicate wells per donor. 470 
 471 
Chemiluminescence protocol for ROS assay                 472 
ROS production in response to the periodontal bacteria (MOI of 1,000) was 473 
determined using enhanced chemiluminescence. Neutrophils (1x105) from five 474 
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different donors were added to a 96-well plate (using triplicate wells per donor) pre-475 
coated with 1% bovine serum albumin (BSA). ROS release following exposure to 476 
PBS (unstimulated negative control), PMA (25 nM, positive control) and opsonised 477 
S. aureus (MOI of 500, positive control) was quantified. Neutrophils were stimulated 478 
after being equilibrated for a 30 min baseline period and then ROS was measured 479 
over the subsequent 100 min. To measure total ROS, extracellular ROS and 480 
superoxide, luminol (3 mM), isoluminol (3 mM) with 1.5 units of horseradish 481 
peroxidase (HRP), and lucigenin (0.25 mg/mL), respectively, were added to the 482 
samples and the light output was read for 130 min in a luminometer (Berthold 483 
Tristar2, Berthold Technologies, Harpenden, UK). All readings were expressed as 484 
relative light units (RLUs) and read at 37°C (MikroWin2000, Informer Technologies, 485 
Madrid, Spain). All reagents for chemiluminescence were purchased from Sigma 486 
Aldrich (Dorset, UK). 487 
 488 
NET entrapment and quantification of NET-mediated killing of periodontal 489 
bacteria 490 
To assess the ability of NETs to immobilise periodontal bacteria, fluorescein 491 
isothiocyanate (FITC)-stained live bacteria (MOI of 100) were incubated for 1h with 492 
unstimulated neutrophils, intact NETs (produced by prior 0.75 mM HOCl stimulation 493 
with a subsequent washing step (43)) or NET structures degraded with micrococcal 494 
nuclease (MNase, New England Biolabs, Hitchin, UK) in a 96-well plate pre-coated 495 
with 1% BSA, using five different donors and triplicate wells per donor. In vitro NETs 496 
are formed within 2-3h, therefore, a relevant induction of NET release from otherwise 497 
unstimulated neutrophils by bacteria could be excluded. Following multiple wash 498 
steps to remove any unbound bacteria, the amount of bacteria entrapped was 499 
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fluorometrically quantified and normalised to FITC-stained bacteria incubated with 500 
PBS (cell-free control). To determine whether NETs are capable of killing entrapped 501 
bacteria, six strains (F. nucleatum subsp. polymorphum, S. intermedius, S. 502 
sanguinis, A. viscosus, V. parvula and C. gingivalis) were incubated at a MOI of 100 503 
with PBS (negative control), unstimulated neutrophils, intact NETs or degraded 504 
NETs from five different donors in triplicate wells per donor. Additionally, samples 505 
containing neutrophils were treated with the phagocytosis inhibitor cytochalasin B 506 
(Sigma Aldrich, Harpenden, UK) at a concentration of 10 μg/mL (72). Following 1h of 507 
incubation bacteria were released from NETs by MNase digestion, diluted and 508 
inoculated onto agar plates and cultured for 24h prior to performing colony counts. 509 
 510 
Effect of NADPH-oxidase pathway modulating agents on ROS and NET 511 
production                      512 
To further understand the importance of NADPH-oxidase and downstream products 513 
in bacteria-induced ROS and NET production, specific components of the NADPH-514 
oxidase signalling pathway were targeted. Isolated neutrophils from three different 515 
donors were incubated with DPI (25 μM), an inhibitor of NADPH-oxidase, NAC 516 
(10 mM), a synthetic glutathione precursor that scavenges H2O2, or taurine 517 
(100 mM), which scavenges HOCl to produce taurine chloramine (duplicate wells per 518 
donor). Neutrophil total ROS and NET production were measured following pre-519 
incubation with the modulating agent for 30 min prior to stimulation with PMA 520 
(50 nM), opsonised S. aureus (MOI of 500) and 8 selected bacteria (MOI of 1000; S. 521 
aureus, V. parvula, F. nucleatum subsp. nulceatum, F. nucleatum subsp. 522 
polymorphum, S. gordonii, C. rectus, A. viscosus and S. noxia). NET-DNA was 523 
quantified with Sytox Green following enzymatic degradation of NET structures with 524 
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MNase. All reagents were purchased from Sigma Aldrich (Dorset, UK). 525 
 526 
Effect of TLR inhibition on ROS and NET production  527 
To better understand the signalling involved in ROS and NET activation, the effect of 528 
TLR inhibitors was investigated. Isolated neutrophils from three different donors were 529 
incubated in duplicate wells per donor with chloroquine (100 μM, Invivogen, 530 
Toulouse, France), an intracellular inhibitor of endosomal TLR 3, 7, 8 and 9, or 531 
OxPAPC (30μg/ml, Invivogen, Toulouse, France), which inhibits intracellular 532 
signalling of activated TLR 2 and 4, or both TLR inhibitors were used simultaneously. 533 
Neutrophil total ROS and NET production were measured following pre-incubation 534 
with the inhibitor for 30 min prior to stimulation with PMA (50 nM), opsonised S. 535 
aureus (MOI of 500) and 8 selected bacteria (MOI of 1000; S. aureus, V. parvula, F. 536 
nucleatum subsp. nulceatum, F. nucleatum subsp. polymorphum, S. gordonii, C. 537 
rectus, A. viscosus and S. noxia).  538 
 539 
Statistical analysis 540 
All statistical analyses were performed in GraphPad Prism 5 software package for 541 
Windows (San Diego, CA, USA). The distribution of data, and thus whether data 542 
were considered parametric or non-parametric, was determined by Kolmogorov-543 
Smirnov tests. Statistical tests employed for the purpose of this study were at a 544 
significance of 0.05. The level of significance is indicated as follows: *, **, *** and **** 545 
denotes <0.05, <0.01, <0.001 and <0.0001, respectively. Kruskal-Wallis and Dunn’s 546 
multiple comparison tests were performed for quantification of ROS and NET 547 
release. One-way ANOVA and Dunnett’s post-hoc tests were employed for NET 548 
entrapment assays. Two-way ANOVA and Bonferroni post-hoc tests were applied to 549 
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calculate significances of pathway modulation and inhibition assays. All quantitative 550 
data are shown as mean values ± standard deviations and all statistical tests were 551 
performed comparing different donors. 552 
 553 
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FIGURE LEGENDS 794 
 795 
Figure 1 796 
Neutrophil ROS production in response to periodontal bacteria. Neutrophil total 797 
reactive oxygen species (ROS) (A), extracellular ROS (B) and superoxide production 798 
(C) were quantified and time-course production assayed over 130 min in response to 799 
periodontal bacteria using luminol, isoluminol and lucigenin enhanced 800 
chemiluminescence, respectively. ROS release in response to PBS (unstimulated 801 
negative control), phorbol 12-myristate 13-acetate (PMA) (25 nM, positive control) 802 
and opsonised S. aureus (positive control) was also quantified. Data are presented 803 
as relative light units (RLU) and represent neutrophils of five different donors 804 
assessed in triplicate wells. 805 
 806 
Figure 2 807 
Quantification of NET production in response to periodontal bacteria. 808 
Neutrophil extracellular trap (NET) production was quantified in response to 809 
periodontal bacteria and to PBS (unstimulated negative control), phorbol 12-810 
myristate 13-acetate (PMA) (50 nM, positive control) and opsonised S. aureus 811 
(positive control). NET-DNA was quantified using Sytox Green assay (A) and NET-812 
bound neutrophil elastase (B), myeloperoxidase (C) and cathepsin G (D) were 813 
quantified colorimetrically. Data are presented as arbitrary fluorescence units (AFU), 814 
U/mL or mU/mL and represent neutrophils of ten different donors assessed in 815 
triplicate wells. 816 
 817 
Figure 3 818 
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NET entrapment of periodontal bacteria. A: Neutrophil extracellular trap (NET) 819 
entrapment of bacteria that were not assigned to a Socransky complex (white, grey, 820 
black), as well as purple, yellow, green, orange, red and blue complex bacteria. 821 
Results are normalised to fluorescein isothiocyanate-stained bacteria in PBS. 822 
Statistical significance of bacterial entrapment in NETs is shown relative to bacteria 823 
entrapped by unstimulated neutrophils and degraded NETs (n.s.=not significant). 824 
Data are presented as arbitrary fluorescence units (AFU) B: Representative images 825 
of bacterial entrapment by NETs. Neutrophils (yellow arrows) incubated with PBS 826 
(control), live A. actinomycetemcomitans serotype a, V. parvula or A. viscosus were 827 
visualised by scanning electron microscopy. Blue arrows indicate NET strand 828 
structures and NET-associated bacteria are indicated with green arrows. 829 
Representative images of three experiments are shown, the scale bar represents 830 
10μm. C: Bacterial survival after exposure to neutrophils, NETs, degraded NETs and 831 
neutrophils with cytochalasin B (n.s.=not significant). All results shown represent 832 
neutrophils of five different donors assessed in triplicate wells. 833 
 834 
Figure 4 835 
Effect of NADPH-oxidase pathway modulating agents on ROS and NET 836 
production. Total reactive oxygen species (ROS) (A) and Neutrophil extracellular 837 
trap (NET) (B) production by neutrophils was quantified in response to selected 838 
periodontal bacteria, as well as to phorbol 12-myristate 13-acetate (PMA) (50 nM) 839 
and opsonised S. aureus (positive controls) following pre-incubation (30 mins) with 840 
diphenyleneiodonium (DPI) (25 μM), N-acetyl-cysteine (NAC) (10 mM) and taurine 841 
(100 mM). Data are presented as relative light units (RLU) and arbitrary fluorescence 842 
units (AFU). Experiments were conducted in duplicate using three different donors.  843 
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 844 
Figure 5 845 
Effect of Toll-like receptor inhibition on ROS and NET production. Total reactive 846 
oxygen species (ROS) (A) and Neutrophil extracellular trap (NET) (B) production by 847 
neutrophils was quantified in response to selected periodontal bacteria, as well as to 848 
phorbol 12-myristate 13-acetate (PMA) (50 nM) and opsonised S. aureus (positive 849 
controls) following pre-incubation (30 mins) with chloroquine (100 μM), oxidised 1-850 
palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (OxPAPC) (30 μg/mL) or 851 
chloroquine and OxPAPC. Experiments were conducted in duplicate wells using 852 
three different donors (n.s.=not significant). 853 
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Table 1 869 
Bacteria used, their assignment to Socransky complexes and growth conditions. 870 
 871 
 872 
Bacterial strain 
ATCC 
number 
Socransky 
complex 
Growth 
conditions 
Actinomyces viscosus  
(naeslundii genospecies 2) 
43146 blue anaerobic 
Aggregatibacter actino-
mycetemcomitans serotype a 
29523 green anaerobic 
Aggregatibacter actino-
mycetemcomitans serotype b 
43718 white anaerobic 
Campylobacter rectus 33238(371) orange anaerobic 
Campylobacter showae 51146 orange anaerobic 
Capnocytophaga gingivalis 33624(27) green anaerobic 
Capnocytophaga sputigena 33612(4) green anaerobic 
Fusobacterium nucleatum  
subsp. nucleatum 
25586 orange anaerobic 
Fusobacterium nucleatum  
subsp. polymorphum 
10953 orange anaerobic 
Porphyromonas gingivalis W83 red anaerobic 
Propionibacterium acnes 11827 white anaerobic 
Selenomonas noxia 43541 white anaerobic 
Staphylococcus aureus 
(opsonised) 
9144 N/A aerobic 
Streptococcus anginosus 33397 yellow 5% CO2 
Streptococcus constellatus 27823(M32b) orange 5% CO2 
Streptococcus gordonii 10558 yellow 5% CO2 
Streptococcus intermedius 27335 yellow 5% CO2 
Streptococcus oralis 35037 yellow 5% CO2 
Streptococcus sanguinis 10556 yellow 5% CO2 
Veillonella parvula 10790 purple anaerobic 





